camurus®

Improving treatments for patients with severe and chronic diseases

Company Presentation
May 2023

Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Camurus snapshot

Rapidly growing commercial stage company

Leader in opioid dependence treatment with Buvidal weekly and monthly depots

Strong financial performance

Entered profitability in 2022

Advancing late-stage pipeline with blockbuster potential

Prospects for multiple new approvals in coming years in CNS and rare disease indications

Unique FluidCrystal® technology platform

Commercially validated, with a broad range of applications

LISTED ON NASDAQ STOCKHOLM
TICKER **CAMX**; EMPLOYEES: ~**190**

Significant recent progress and near-term milestones

Strong financial performance

- ✓ High double-digit year-on-year revenue growth
- ✓ Profitability since 2022
- ✓ Robust cash position SEK 586 m – no debt

Commercialization execution

- ✓ Leader in long-acting opioid dependence treatment in the EU and Australia
- ✓ Strong sales growth supported by an expanding evidence base
- ✓ Further potential through label and geographic expansion

Pipeline advancement

- ✓ Imminent approval decision for Brixadi in the US
- ✓ Four Phase 3 studies in rare disease indications
- ✓ Results from pivotal Phase 3 efficacy study of CAM2029 in acromegaly expected in June 2023

camurus.

Leading FluidCrystal extended-release technology

- ✓ Easy and convenient administration
- ✓ Rapid onset & long-acting release
- ✓ Applicable across substance classes
- ✓ Adopted to prefilled syringes and prefilled pens
- ✓ Manufacturing by standard processes
- ✓ Strong intellectual property



Sources: Tiberg F, et al. Chapter in Long Acting Injections and Implants, Advances in Delivery Science and Technology 2012; Tiberg F, et al. OnDrugDelivery 2010; Tiberg F, et al. Drug Del. Sci. Tech., 21 (1) 101-109 2011.

FluidCrystal – Long-acting release

Immediate release pasireotide (Signifor®)



Pasireotide FluidCrystal® (CAM4071)



Opioid dependence – escalating global health crisis

Largest society burden of all drugs[1]

– 61 million opioid users worldwide[1]
– Opioid crisis worsened during COVID-19 pandemic

High need for better access to care and new treatment alternatives

– Long-acting injections a new paradigm in opioid dependence treatment

Significant limitation with current daily medications

– Diversion, misuse, risk of overdose, poor retention, burdens and stigma of daily medications

Escalating opioid overdose deaths





[1] United Nations: World drug report 2022 [2] SAMSHA; [3] EMCDDA; [4] www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
[5] https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-in-scotland/2020

camurus.

Buvidal – game changing opioid dependence treatment

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over[1]

Demonstrated significant benefits to patients and society

- Superior treatment outcome and patient satisfaction[2-5]
- Blockade of subjective opioid effects from first dose[3]
- Reduced treatment burden and improved quality of life[5,6]
- Decreased risk of diversion, misuse and pediatric exposure[7,8]
- Reduced treatment costs[9]

[1] SmPC Buvidal May 2021; [2] Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; [3] Walsh et al, JAMA Psychiatry 2017;74(9):894-902; [4] Frost , M., et al. Addiction. 2019;114(8):1416-1426. doi: 10.1111/add.14636; [5] Lintzeris, N., et al. JAMA Network Open. 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041, [6] Barnett et al Drug and Alcohol Dependence 2021; https://doi.org/10.1016/j.drugalcdep.2021.108959 ; [7] EPAR for Buvidal; [8] Dunlop, A. J., et al. Addiction. 2021. https://doi.org/10.1111/add.15627; [9] Dunlop, A. Oral presentation at CPDD June 2020.

Buvidal continuing to grow in Europe, Australia and MENA

Leader in opioid dependence treatment

– Continued high market penetration with Buvidal
  - >20% of treated patients in Australia and Nordics
  - UK exceeding 5% patient share (~20% of the buprenorphine segment)
– Est. 39,000 patients in treatment with Buvidal end Q1 2023

Regulatory and market expansion processes

– Marketing authorization in the United Arab Emirates
– Price and reimbursement approvals in Greece and UAE
– Four regulatory applications for Buvidal and four PMA submissions under review
– Increased use of Buvidal in criminal justice systems
– Variation application to expand Buvidal indication to chronic pain in opioid dependent patients withdrawn

Quarterly product sales



Brixadi™ approved for treatment of OUD in the US

Brixadi[1] approved in the US

- ✓ NDA approval of Brixadi by the US FDA 23 May 2023 for the treatment of opioid use disorder (OUD)[2]
- ❑ US commercialization by Braeburn under license agreement with Camurus

Significant market opportunity in the US

- High medical need with 80,000 annual deaths in opioid overdoses[3]
- New government initiatives to improve access to OUD treatment[4-6]
- Growing OUD market driven by long-acting injectables[7-8]
- Brixadi is well differentiated and positioned

Large medical need and treatment gap



NDA – New Drug Application

[1] Brixadi™ Prescribing Information [2] Brixadi™ is the US trade name for Buvidal®; [3] CDC Provisional Drug Overdose Death Counts; [4] H.R.2471 - Consolidated Appropriations Act, 2022; [5] The White House – Consolidated Appropriations Act, 2023; [6] Justice Department Issues Guidance on Protections for People with Opioid Use Disorder, 5 Apr 2022; [7] Fortune Business Insights 2023; [8] GlobalData 2023, sales data and analyst consensus including expected Sublocade® and Brixadi™ sales; [9] 2018 National Survey on Drug Use and Health; [10] Keyes KM, et al. Drug Alc. Dep. Reports 2022 ; [11] CDC 2023; [12] Symphony Health data

camurus.

Recent initiatives to address treatment hurdles in the US

President Biden's Unity Agenda[1]

– Combating opioid epidemic key item in State of the Union 2022 and 2023

Increased funding of treatment[2]

– Over $6 billion to address opioid epidemic and substance misuse in 2022



Improved access to treatment[3]

– DATA 2000 waiver removed
– Removed limitation on the number of patients a healthcare professional can treat with medication
– Increased number of days HCPs can store buprenorphine in the clinic from 14 to 45 days

Expand access to patients in criminal justice system[4]

– New guidance on OUD treatment within criminal justice system issued by Department of Justice

[1] State of the Union 2023; [2] H.R.2471 - Consolidated Appropriations Act, 2022; [3] The White House – Consolidated Appropriations Act, 2023; [4] Justice Department Issues Guidance on Protections for People with Opioid Use Disorder, 5 Apr 2022

US opioid use disorder market expected to grow to >$3.5 billion in five years

Forecasted North America opioid use disorder (OUD) market size[1]



Expected growth primarily from buprenorphine LAI products[2]



* Forecast based on analyst consensus data

[1]Fortune Business Insights 2023; [2]GlobalData 2023, sales data and analyst consensus including expected Sublocade® and Brixadi™ sales; [3]Patient share estimated based on average patient months calculated from dispensed Sublocade® units (Indivior FY22 report) and total treated patients from Symphony Health data

Buprenorhine LAI share 2022

~18%

of overall OUD market value

with only

3-5%

of treated patients[3]

camurus.

Brixadi and Buvidal – well differentiated

Flexible dosing and posology

– Weekly and monthly dosing
– Multiple dose options (four weekly, three monthly)
– Choice of multiple injection sites (buttock, thigh, abdomen or upper arm)
– Thin needle and small dose volumes

Easy switch from daily medication

– Switch from daily sublingual buprenorphine using conversion table for dose equivalency

Enabling treatment initiation on Day 1

– Direct initiation of treatment following a single dose of transmucosal buprenorphine

Improved storage

– Room temperature (no cold chain required)

LAI features[1]	Sublocade	Vivitrol	Brixadi
Weekly dosing	–	–	✓
Monthly dosing	✓	✓	✓
Multiple doses	–	–	✓
Choice of inj. sites	–	–	✓
Smallest needle	(19G)	(20G)	✓ (23G)
Lowest dose volume	0.5–1.5mL	3.4mL	✓ 0.16–0.64mL
Room temp. storage	–	–	✓
Day one initiation	–	–	✓
Clin. data vs active control	–	–	✓
Launched	US, CAN, AUS,SE, FI, IL	US	EU, UK, AUS

LAI – long acting injectable
[1]See product information

Broad and diversified mid- to late-stage pipeline



[1]Licensed to Braeburn in North America; [2]Licensed to Rhythm Pharmaceuticals worldwide

Octreotide SC depot

CAM2029 under assessment in three serious rare-disease indications

- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
- Polycystic liver disease (PLD)

Designed for enhanced efficacy and patient convenience

CAM2029 targeting USD 3-billion SSA market

SSAs established treatment with limitations

– First-line treatment of acromegaly and neuroendocrine tumors (NET)
– Established safety and efficacy profile
– Potential for significant improvements of efficacy and patient convenience

CAM2029 best-in-class treatment potential

– Convenient self-administration with state-of-the-art pen device

– 5-fold increase of octreotide plasma exposure (dose adjusted)
– Potential for improved disease control and treatment outcomes

Annual sales of first generation SSAs[1]



[1] *GlobalData 2022*

camurus.

CAM2029 Phase 3 programs advancing



Timelines are indicative. PK – pharmacokinetic; PD – pharmacodynamic; RCT – Randomized control trial; LST – Long-term safety trial; ACRO – acromegaly, GEP-NET – gastroenteropancreatic neuroendocrine tumors; PLD – polycystic liver disease; OLE – open label extension

camurus

CAM2029 provides high SSA exposure

- ~5x higher octreotide plasma exposure for CAM2029 vs. Sandostatin LAR
- CAM2029 octreotide plasma levels in the range of immediate release octreotide



SSA – somatostatin analog; PK – pharmacokinetic; IR – immediate release; LAR – long-acting release; TID – three times per day; q4w – every 4 weeks
Data on file

camurus

CAM2029 provides high SSA exposure

- ~5x higher octreotide plasma exposure for CAM2029 vs. Sandostatin LAR
- CAM2029 octreotide plasma levels in the range of immediate release octreotide



SSA – somatostatin analog; PK – pharmacokinetic; IR – immediate release; LAR – long-acting release; TID – three times per day; q4w – every 4 weeks
Data on file

ACROINNOVA 1: Phase 3 efficacy trial in acromegaly

Pivotal randomized, placebo-controlled Phase 3 trial

- Rigorous, 24-week, randomized, double-blind, placebo-controlled trial of CAM2029 in patients with acromegaly
- Filling regulatory requirement for efficacy

Patient population

- Acromegaly patients on stable doses of long-acting octreotide or lanreotide with IGF-1 levels ≤1xULN and mean GH cycle levels <2.5 µg/L at screening

Primary endpoint

- Proportion of patients with mean IGF-1 levels ≤1x upper limit of normal (ULN) at Week 22 and Week 24 (average of the 2 measurements)

Secondary endpoints:

- Biochemical response (IGF-1, GH)
- Clinical signs and symptoms
- Tumor size
- PROs (e.g., treatment satisfaction, quality of life)
- Plasma concentrations of octreotide
- Safety



IGF-1 – insulin-like growth factor 1; ULN – upper limit of normal; GH – growth hormone; PRO - patient reported outcome

ACROINNOVA 2:
Phase 3 long-term safety trial in acromegaly

Long-term safety Phase 3 trial

- 52-week long-term safety, switch and extension trial of CAM2029 in patients with acromegaly
- Filling regulatory requirements for safety exposure

Patient population

- Incomplete IGF-1 responders
- Complete IGF-1 responders
- Patients with prior pituitary radiotherapy (3 years cut-off)
- Roll-over CAM2029 and placebo patients from ACROINNOVA 1

Primary endpoint

- Safety and tolerability of CAM2029

Secondary endpoints include

- Biochemical response (IGF-1, GH)
- Clinical signs and symptoms
- Tumor size
- PROs (treatment satisfaction, quality of life, self/partner-administration
- Plasma concentrations of octreotide



IGF-1 – insulin-like growth factor 1; ULN – upper limit of normal; GH – growth hormone; PRO - patient reported outcome

camurus.

SORENTO:
Largest Phase 3 trial of SSA in NET

Randomized, active-controlled Phase 3 trial

- Randomized, multi-center, open-label, active-controlled Phase 3 trial of CAM2029 vs. long-acting octreotide or lanreotide in patients with GEP-NET
- Single trial fulfilling regulatory requirements for safety and efficacy

Patient population

- Patients with confirmed, advanced (unresectable and/or metastatic), and well-differentiated GEP-NET (grade 1 to grade 3)

Primary endpoint

- Superiority in progression free survival, PFS, vs. standard of care (first-line medical treatment)
- Assessed after 194 progression events

Secondary endpoints include

- Overall survival
- PROs (e.g., treatment satisfaction, quality of life)
- Plasma concentrations of octreotide
- Safety



GEP-NET – gastroenteropancreatic neuroendocrine tumors; PFS – progression free survival; PRO - patient reported outcome; LAR – long-acting release; ATG - autogel

camurus.

CAM2029 clinical trials status update

AcroInnova™

Pivotal randomized placebo controlled and long-term safety trials in acromegaly

- ✓ Two Phase 3 trials ongoing, ACROINNOVA 1 and 2
- ✓ Patient recruitment goals reached in both trials
- ✓ Last dose administrated in ACROINNOVA 1
- ❑ **Topline ACROINNOVA 1 efficacy results June 2023**
- ❑ Interim ACROINNOVA 2 results in Q3 2023
- ❑ Target NDA and MAA submissions late 2023 / early 2024

SORENTO™

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine TumOrs

- ✓ SORENTO Phase 3 trial ongoing
- ✓ **>50% of 302 patients enrolled**
- ❑ **Estimated enrollment completion H2 2023**
- ❑ Completion SORENTO efficacy part after 194 PFS events
- ❑ Estimated NDA/MAA submissions 2025

positano™

Polycystic liver Safety and efficacy TriAl with subcutaneous Octreotide

- ✓ Orphan drug designation (US)
- ✓ New PROs developed and aligned with FDA
- ✓ Phase 2b trial started June 2022
- ❑ **Estimated enrollment completion H2 2023**
- ❑ Topline results 2024

Ongoing preparations for launches of CAM2029

Manufacturing

- ✓ Commercial manufacturing process established
- ✓ Process validation completed
- ❑ Stability studies for submissions ongoing

Commercial – EU and Australia

- ✓ Scalable commercial infrastructure
- ✓ Pre-launch preparations initiated – medical team expanded
- ❑ Stepwise commercial team build-up along with approvals in each indication

Commercial – US

- ✓ Establishment of own US commercial infrastructure initiated
- ❑ Ready mid-2024

Medical affairs – activities Q1 2023

- – Investigator meeting in the SORENTO study held at the European NeuroEndocrine Tumor Society (ENETS) meeting 22-24 March 2023 in Vienna, Austria
- – Three meeting abstracts accepted for presentation at ISPOR in Boston in May and ENDO in Chicago in June

Scientific conferences

Large market potential for CAM2029

Attractive opportunity

- Block buster potential in NET
- Highly concentrated target audiences
- Differentiated product features
- Switch opportunity from established first-line treatments

CAM2029 peak sales estimates from third party market research[1-4]

	TERRITORY	PATIENT POPULATION	EST. PEAK PATIENT SHARE	EST. PEAK SALES
ACRO[1]	EU/AUS	16,500[4]	20 – 35%	€30 – 65 million
	US	**10,000**	**25 – 40%**	**$150 – 280 million**
NET[1]	EU/AUS	68,000[4]	30%	€300 – 400 million
	US	**37,000**	**40%**	**$1,200 – 1,500 million**
PLD[1]	EU/AUS	15-18,000[4]	30 – 40%	€80 – 100 million
	US	**12-13,000**	**30 – 40%**	**$200 – 300 million**

GlobalData report[5]

"Top selling drug to enter the market will be Camurus' Octreotide LA"

Estimates CAM2029 sales of **US$210m** US+EU4+UK sales in 2029 in acromegaly

[1]Globe Life Science Aug 2022, data on file; [2]Globe Life Science 2020, data on file; [3]Assuming €10-12.5ks (EU/AUS) and $60-70K (US) per year net pricing in acromegaly, €15-20k (EU/AUS) and $80-100K (US) per year net pricing in NET, and €17.5k (EU/AUS) and $60K (US) per year net pricing in PLD; [4]Patient numbers extrapolated from 5EU estimates by assuming same prevalence across European countries and Australia

Key take-aways May 2023

- Strong start to the year with robust top and bottom-line growth
- Buvidal market penetration and expansion continues
- Significant progress in the late-stage R&D pipeline
- Brixadi approved in the US for OUD on 23 May 2023
- Phase 3 results for CAM2029 late June

Past and expected milestones in 2023

Advancing the pipeline

- ❑ Topline Phase 3 efficacy results in acromegaly
- ❑ First readout Phase 3 long-term safety study
- ❑ Pre NDA meeting for CAM2029 in acromegaly
- ❑ Completed recruitment in SORENTO study in GEP-NET
- ❑ Completed recruitment in POSITANO study in PLD
- ❑ Topline Phase 3 PK results for weekly setmelanotide by Rhythm
- ❑ Start Phase 3 “de novo” study of weekly setmelanotide by Rhythm

Commercial and corporate development

- ✓ US approval and launch of Brixadi in opioid dependence
- ❑ Establishment of US commercial infrastructure
- ❑ Business development and inorganic growth

Q&A

Camurus AB | Ideon Science Park, SE-223 70 Lund, Sweden
P +46 46 286 57 30 | info@camurus.com | camurus.com

Experienced and committed management team

Fredrik Tiberg, PhD
President & CEO, CSO
In Company since: *2002*
Holdings*: 1,680,000 shares, 15,000 subscription warrants & 102,000 employee options*

Education: M.Sc. in Chem. Eng., Lund Institute of Technology, PhD and Assoc. Prof. Physical Chemistry, Lund University.
Previous experience: More than 20 years leadership experience from the pharmaceutical industry. Professor Physical Chemistry at Lund University, Sect. Head Institute Surface Chemistry, Visiting Professor at Oxford University

Maria Lundqvist
Head of Global HR
In Company since: *2021*
Holdings*: 1,000 subscription warrants and 38,500 employee options*

Education: B.Sc: in Business and Economics, Uppsala University
Previous experience: More than 20 years of experience of leadership roles within Human Resources, including HR Director Nordics at Teva Pharmaceuticals and HR positions at Tetra Pak, Vestas and AstraZeneca.

Fredrik Joabsson, PhD
Chief Business Dev. Officer
In Company since: *2001*
Holdings*: 50,170 shares & 38,500 employee options*

Education: M.Sc. in Chemistry, PhD in Physical Chemistry, Lund University
Previous experience: More than 20 years of experience in pharmaceutical R&D, business development and alliance management.

Torsten Malmström, PhD
Chief Technical Officer
In Company since: *2013*
Holdings*: 46,858 shares & 38,500 employee options*

Education: M.Sc. in Chemistry, PhD in Inorganic Chemistry, Lund University
Previous experience: More than 20 years of experience from pharmaceutical R&D including Director Pharmaceutical Development at Zealand Pharma, Director of Development at Polypeptide, Team Manager at AstraZeneca.

Agneta Svedberg
VP Clinical & Regulatory Dev.
In Company since: *2015*
Holdings*: 22,987 shares & 38,500 employee options*

Education: M.Sc. In Radiophysics and B.Sc. In Medicine from Lund University, Executive MBA from Executive Foundation Lund
Previous experience: More than 25 years of experience in drug development, incl. as COO at Zealand Pharma, CEO of Cantargia, Senior VP Clinical Development at Genmab.

Jon Garay Alonso
Chief Financial Officer
In Company since: *2022*
Holdings*: 1,450 shares & 57,750 employee options*

Education: Bachelor in Business Administration by Universidad Comercial de Deusto. Executive MBA by IESE Business School.
Previous experience: More than 20 years experience from Finance within pharmaceutical and medtech companies, incl. Baxter, Gambro, Convatec, Bristol Myers Squibb.

Richard Jameson
Chief Commercial Officer
In Company since: *2016*
Holdings*: 29,193 shares, 8,000 subscription warrants and 57,750 employee options*

Education: B.Sc. in Applied Biological Sciences from University West of England
Previous experience: General Manager, UK & Nordics for Reckitt Benckiser (2010 – 2013) and Area Director Europe, Middle East and Africa for Indivior (2013 – 2016).

Markus Johnsson
Senior VP R&D
In Company since: *2003-2017, 2019-*
Holdings*: 21,000 shares & 23,500 employee options*

Education: Ph.D. in physical chemistry and M.Sc. in chemistry from Uppsala University.
Previous experience: More than 20 years of experience from pharmaceutical development and project management

Annette Mattsson
VP Regulatory Affairs
In Company since: *2017*
Holdings*: 2004 shares & 38,500 employee options*

Education: Bachelor of Pharmacy, Uppsala University and Business Economics, Lund University
Previous experience: More than 25 years of experience within regulatory affairs, including European RA Director/Global RA Lead at AstraZeneca and Global RA Lead at LEO Pharma.

Shareholders and analyst coverage

Shareholders as of 30 April	Number of shares	% of capital	% of votes
Sandberg Development AB	21,875,692	39.5	39.5
Fjärde AP-fonden	3,116,100	5.6	5.6
Avanza Pension	2,277,315	4.1	4.1
Didner & Gerge Fonder	2,024,044	3.6	3.6
Fredrik Tiberg, CEO	1,680,000	3.0	3.0
State Street Bank and Trust	1,090,029	2.0	2.0
JP Morgan Chase Bank	921,073	1.7	1.7
Backahill Utveckling	826,491	1.5	1.5
Svenskt Näringsliv	800,000	1.4	1.4
Lancelot Avalon	600,000	1.1	1.1
Öhman Fonder	593,555	1.1	1.1
Afa Försäkring	569,060	1.0	1.0
Camurus Lipid Research Foundation	486,350	0.9	0.9
Handelsbankens fonder	457,293	0.8	0.8
COJ Service AB	425,000	0.8	0.8
Other shareholders	17,681,041	31.9	31.9
In total	**55,423,043**	**100.0**	**100.0**

Analysts

Carnegie
Erik Hultgård

DNB
Patrik Ling

Handelsbanken
Suzanna Queckbörner
Mattias Häggblom

Jefferies
James Vane-Tempest

Nordea
Viktor Sundberg

Pareto
Peter Östling

Bryan Garnier
Alex Cogut